公开(公告)号：EP2638402A2

公开(公告)日：2013-09-18

申请号：EP11844895.0

申请日：2011-11-08

申请人： The Government of The United States of America, as represented by the Secretary, Department of Health and Human Services,

发明人： BOYER, Anne E. ,  LINS, Renato C. ,  KUKLENYIK, Zsuzsanna ,  GALLEGOS-CANDELA, Maribel ,  QUINN, Conrad P. ,  BARR, John R.

IPC分类号： G01N33/68 ,  C12Q1/25 ,  G01N33/543 ,  G01N33/569

CPC分类号： G01N33/56911 ,  C12Q1/527 ,  G01N2333/32 ,  G01N2333/988

摘要： One major problem in diagnosis methods presently available for anthrax is that these methods require several days to produce a result, are rendered unusable after antibiotic use, or are not quantifiable. The only existing treatment for anthrax requires administration soon after infection at a time when patients are exhibiting only mild flu-like symptoms. Thus, by the time a diagnosis is made a patient may be days beyond the time when treatment would be effective. The present invention reduces diagnosis time to as little as four hours providing same day identification of anthrax radically increasing the odds of delivering proper treatment and patient recovery. The rapid identification of anthrax edema factor activity exhibited by the invention is also amenable to in vivo screening protocols for the discovery and development of anthrax vaccines, anti-toxins and edema factor inhibitors. The invention isolates and concentrates edema factor and edema toxin from nearly any sample. By capitalizing on the adenylate cyclase activity of edema factor the invention amplifies output signals producing reliable detection of low concentrations of edema factor previously unachievable. The invention involves novel purification and detection techniques and substrates for rapid, reproducible, and quantitative measurements of anthrax edema factor, and other adenylate cyclases in biological samples.